NDC 57319-455-43 - Thyrozine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 57319-455
- Requested NDC
- 57319-455-43
- Package NDCs from labels
- 57319-455-27, 57319-455-43
- Manufacturer
- PHOENIX PHARMACEUTICAL INC./ CLIPPER DISTRIBUTING, INC. | FIRST PRIORITY INCORPORATED
- Effective date
- 2018-01-19
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Thyrozine Powder | PHOENIX PHARMACEUTICAL INC./ CLIPPER DISTRIBUTING, INC. | FIRST PRIORITY INCORPORATED | 2018-01-19 | OTC ANIMAL DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 57319-455-27 | Thyrozine | 12 in 1 CASE | POWDER | 12 | 1 | |
| 57319-455-27 | Thyrozine | 453.6 g in 1 JAR | POWDER | 453.6 | 1 | |
| 57319-455-43 | Thyrozine | 4536 g in 1 PAIL | POWDER | 4536 | 1 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | ONESOURCE SPECIALTY PHARMA LIMITED | ae9954a5-e196-449c-abea-ebe4afbee517 | 2026-08-12 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | MAIA Pharmaceuticals, Inc. | 4e9adc35-3aba-4a0d-9c4e-7e7ee2ffdabd | 2026-08-05 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Piramal Critical Care, Inc. | 76139990-1355-cfb6-e053-2991aa0ace5b | 2025-09-25 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Zydus Pharmaceuticals USA Inc. | bf8a952c-f05b-4814-b55a-ed04be015269 | 2025-09-16 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fosun Pharma USA Inc. | 3361138a-6e6f-e8df-e063-6294a90af2de | 2025-05-05 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | ENDO USA, Inc. | 9d815416-11c9-470e-a82f-89b0bf232e12 | 2025-04-28 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fresenius Kabi USA, LLC | ce990712-49c1-4f66-9ee4-c770e8ec394c | 2025-04-17 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fresenius Kabi USA, LLC | 152d071f-d4aa-46d2-b397-61c1cabdd86d | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Fresenius Kabi USA, LLC | f88f44d8-2f18-4155-9d78-6323d19fbafe | 2024-10-14 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM ANHYDROUS | Sagent Pharmaceuticals | f57e9b19-6f17-4520-80fc-511322cc56c9 | 2023-10-19 | Boxed warning, Warnings, Adverse reactions | 054I36CPMN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.